Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of N-acetylcysteine in preparation of product for treating biliary atresia and medicine for treating biliary atresia

A technology for acetylcysteine ​​and biliary atresia, which is applied in the field of medicines for treating biliary atresia, can solve problems such as lack of drug treatment, and achieves the effects of reliable safety, decreased direct bilirubin and total bilirubin, and improved treatment.

Inactive Publication Date: 2021-08-06
GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no effective drug treatment for this disease, so finding a drug that can effectively improve the clinical symptoms of biliary atresia has great clinical significance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of N-acetylcysteine in preparation of product for treating biliary atresia and medicine for treating biliary atresia
  • Application of N-acetylcysteine in preparation of product for treating biliary atresia and medicine for treating biliary atresia
  • Application of N-acetylcysteine in preparation of product for treating biliary atresia and medicine for treating biliary atresia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] 1. Materials

[0044]Experimental reagents: DCFDA / H2DCFDA-Cellular ROS Assay kit (ab113851), AssayHoechst 33342 Staining Dye Solution (ab228551), 7-AAD (ab228563), PE fluorescently labeled anti-human CD177 antibody (ab69777, Abcam), Human Fc Block (564765) , APC-Cy7 fluorescently labeled anti-human CD45 antibody (557833, BD Biosciences), Anti-PE microbeads (130-048-801, Miltenyi Biotec), MitoTrackeTM Red CMXRos (M7512, thermo scientific), MitoTracker TM Green FM (M7514, thermo scientific).

[0045] Experimental equipment: magnetic cell sorter (Miltenyi Biotec, Germany), laser confocal microscope (Leica DMI8, Germany), BD FACS Aria II flow cytometer (BD Biosciences, USA).

[0046] 2. Experimental steps

[0047] 1) Grouping

[0048] Twelve children with biliary atresia were randomly divided into two groups, NAC treatment group and non-NAC treatment group, with 6 children in each group, half male and half male, and an informed consent was signed before treatment. A nor...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of N-acetylcysteine in preparation of a product for treating biliary atresia and a medicine for treating biliary atresia, and relates to the technical field of disease treatment. According to the application of N-acetylcysteine in preparation of the product for treating the biliary atresia, the research of the inventor finds that after N-acetylcysteine is administered to treat children with biliary atresia, the number of CD177<+> neutrophils and cell viability (ROS level, mitochondrial level and extracellular trap level) of the children with biliary atresia are obviously reduced, direct bilirubin and total bilirubin are obviously reduced, N-acetylcysteine has an improvement effect on treatment of biliary atresia, and the N-acetylcysteine is reliable in safety and can be used for preparing products for treating biliary atresia. The medicine for treating the biliary atresia comprises N-acetylcysteine, and has a treatment effect on the biliary atresia.

Description

technical field [0001] The invention relates to the technical field of disease treatment, in particular to the application of N-acetylcysteine ​​in the preparation of products for treating biliary atresia and the medicine for treating biliary atresia. Background technique [0002] Biliary atresia (BA) is a common disease causing neonatal obstructive jaundice, with poor prognosis and high mortality. The etiology and pathogenesis are still unknown. The basic pathological changes were progressive inflammation of intrahepatic and extrahepatic bile ducts and liver fibrosis. my country is an area with a high incidence of biliary atresia, with an incidence rate of 1 / 5000-1 / 10000. Most of the children were found at 1-3 months after birth, and most of them died of liver failure within 1.5 years because they could not perform liver transplantation. At present, there is no effective drug treatment for this disease, so it is of great clinical significance to find a drug that can effec...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/198A61P1/16
CPCA61K31/198A61P1/16
Inventor 张锐忠苏亮常嘉明陈严陈唯一温哲钟微曾纪晓刘斐王哲夏慧敏
Owner GUANGZHOU WOMEN AND CHILDRENS MEDICAL CENTER
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com